Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2002

View Archived Issues

Versicor and Pharmacia focus on improving activity and spectrum of oxazolidinones

EMEA recommends approval for desloratadine syrup and rapidly disintegrating tablets

Lexicon validates new drug target in depression

Sepracor and 3M join forces to manufacture Xopenex HFA metered-dose inhaler

Vertex moves new drug candidate VX-799 into development for sepsis

Successful completion of clinical trial of inhaled human growth hormone

Actimmune enters phase II trial for treatment of liver fibrosis

Pilot study evaluates Natrecor in chronic heart failure outpatients

Avaden hormone replacement therapy receives French approval

Prescient NeuroPharma licenses anhydrovinblastine to Access Oncology

Major European launch announced for Kaletra

Endothelial cell-specific inhibition of protein synthesis demonstrated for tumstatin

Antisense oligonucleotide targeting Ki-ras as an approach to colorectal cancer

Specific, small-molecule inhibitor of P-selectin with antiinflammatory properties

Cell adhesion inhibitor IS-741 effective in rat model of IBD

Potent and selective OX2 receptor antagonists identified by Banyu

Gastric and cholecystokinin receptor ligands claimed in patents by James Black researchers

New Kissei compounds have potential for lowering lipids and protecting the liver

HGS and CAT form TRAIL-R1 antibody partnership

5-HT7 receptor antagonists synthesized at BMS

Solvay presents piperazine and piperidine compounds and potential uses

CD40-targeted MAb moves to clinical development at Genentech

Alexion's 5G1.1 completes phase I pilot study

DGI BioTechnologies and Novo Nordisk enter collaboration for cancer agents

CSL obtains marketing and distribution license to Angiomax in Australia

Two phase II trials of Neotrofin initiated in chemotherapy-induced neuropathy

MC-1 receives FDA approval for entry into phase II

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...